Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand | BMC Cancer | Full Text

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand | BMC Cancer | Full Text

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand

Chemoradiotherapy (CRT) with high cumulative doses (CDs) of cisplatin has been considered the standard of care for non-metastatic nasopharyngeal carcinoma (NPC). However, given most patients’ inability to tole...

Authors:Nuttapong Ngamphaiboon, Arunee Dechaphunkul, Jiraporn Setakornnukul, Tanadech Dechaphunkul, Rungarun Jiratrachu, Bhoom Suktitipat, Chuleeporn Jiarpinitnun, Poompis Pattaranutaporn and Pongwut Danchaivijitr

Citation:BMC Cancer 2020 20:518

Content type:Research article

 

Published on: 3 June 2020

• ViewFull Text
 
• ViewPDF